Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis.We determined whether avacopan (CCX168), an orally administered, selective C5a receptor inhibitor, could replace oral glucocorticoidswithout compromising efficacy. In this randomized, placebo-controlled trial, adu